Lessons from an unfavorable gene therapy test for Duchenne muscular dystrophy

.Nature Medication, Posted online: 09 Oct 2024 doi:10.1038/ s41591-024-03316-9Delandistrogene moxeparvovec acquired FDA authorization after an adverse trial, which highlights the many difficulties and also difficulties of medication growth in this setting.